Case studies
Proven in the field.
A selection of the programs we have carried through development and approval. Much of our work is covered by confidentiality, so further references are available on request.
Gastric-retention MR program for diabetes
Boston-based biotech · NCE · Phase 1 to 3 CMC · Approved January 2023
Challenge
A new chemical entity for diabetes that needed a gastric-retention modified-release tablet to deliver the target release profile.
Approach
Formulation development and scale-up through Phase 1 to 3 CMC, then tech-transfer for process-validation batches.
Outcome
Approved and launched in the US in January 2023.
Want references relevant to your program? Tell us the molecule, the indication and the stage, and we will put you in front of the ones that match.
Request a consultation
Credible partners for pharmaceutical & life-sciences clients. Evidence-led advisory in CMC, regulatory, quality and strategy for NCEs, generics and branded-generics.
© 2026 Credence Pharma Consulting Inc. All rights reserved.